This is the electronic supporting information (ESI) for:

Chemical Communications 54.63 (2018): 8729-8732

DOI: https://doi.org/10.1039/C8CC04346A

Copyright: © The Royal Society of Chemistry 2018

Access to the published version may require subscription
Electronic Supporting Information

Uracil grafted imine-based covalent organic framework for nucleobase recognition

Sergio Royuela, Eduardo García-Garrido, Miguel Martín-Arroyo, María J. Mancheño, María M. Ramos, David Gonzalez, Alvaro Somoza, Félix Zamora and José L. Segura

Departamento de Química Orgánica I, Facultad de CC. Químicas, Universidad Complutense de Madrid, Madrid 28040, Spain
Departamento de Tecnología Química y Ambiental, Universidad Rey Juan Carlos, Madrid 28933, Spain
Instituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA-Nanociencia), Cantoblanco, Madrid E-28049, Spain.
Departamento de Orgánica, Facultad de Ciencias, Universidad Autónoma de Madrid, Madrid 28049, Spain.
Departamento de Inorgánica, Facultad de Ciencias, Universidad Autónoma de Madrid, Madrid 28049, Spain.
Condensed Matter Physics Center (IFIMAC). Universidad Autónoma de Madrid. 28049 Madrid, Spain.
**General methods.** All reactions with air-sensitive materials were carried out under Ar using standard Schlenk techniques. TLC was performed using pre-coated silica gel 60 F254 and developed in the indicated solvent system. Compounds were visualized under UV light (λ = 254 nm). Merck 60 (230–400 Mesh) silica gel was used for column chromatography.

$^1$H NMR and $^{13}$C NMR spectra were recorded on a 300 MHz spectrometer. Chemical shifts are reported in ppm and referenced to the residual non-deuterated solvent frequencies (CDCl$_3$: δ 7.26 ppm for $^1$H, 77.0 ppm for $^{13}$C). CP/MAS-$^{13}$C NMR were recorded on a 400 MHz spectrometer Wide Bore (probe: 4 mm MAS WB DVT). The sample rotation frequency was 12 kHz and a 2.5 mm ZrO$_2$ rotor was used. Mass spectra were recorded by means of MALDI-TOF or FAB/IE techniques. Solids were analysed on a diamond plate (ATR) or as films on sodium chloride.

**Powder X-ray diffraction**

Powder X-ray diffraction measurements were carried out with X’PERT MPD with conventional Bragg-Brentano geometry using Kα ($λ = 1.5406$ Å) for values of 2θ from 2° to 40°.

**Thermogravimetric analysis**

Thermogravimetric analysis was performed on a TGA-Q-50 instrument on a platinum plate, heating the samples under nitrogen atmosphere at a heating rate of 10 °C/min.

**UV-visible spectroscopy**

UV-visible spectra data were recorded in a Synergy H4 Hybrid reader using 96 well plates.

**Materials**

The following reagents were commercially available and were used as received: 2,5-dimethoxyterephthaldehyde (DMTA), CuI, o-DCB, $n$-butanol, NaN$_3$ and DIPEA.

2,5-dihydroxyterephthaldehyde (DHTA),$^1$ 2,5-bis(prop-2-in-1-yloxy)terephthaldehyde (BPTA),$^1$ 1,3,5-tris-(4-aminophenyl)benzene (TAPB),$^2$ [HC≡C]$_{0.5}$-TPB-DMTP-COF,$^1$ were prepared according to reported procedures.

Adenine, cytosine, uracil and thymine were obtained from Sigma-Aldrich. All the compounds were used without further purification.
Nucleobase interaction studies

Stock solutions of each nucleobase (3.7 mM) in water were prepared. Each COF (0.5 mg) was vortexed for 1 min with a solution of each nucleobase at three different concentrations (50, 100 and 150 μM). The final volume of each sample was 600 μL. Control experiments using the nucleobases were done at the same concentrations. The samples were incubated at room temperature for the time indicated in the figures and centrifuged at 4 °C for 45 min at 13000 rpm (around 15700 g). The supernatants were collected, the absorbance recorded and the amount of free nucleobases quantified applying Beer-Lambert law. All the experiments were done in triplicates. Statistical analysis was performed using one-way ANOVA Tukey’s test (each group vs Control). *P<0.01, **P<0.001, and ***P<0.0001.

Synthesis of the azide-substituted Uracil

1-azido-3-bromopropane was synthesized following a described procedure\textsuperscript{3b} using 1,3-dibromopropane (10.7 mL, 105.4 mmol), NaN\textsubscript{3} (7.5 g, 115.4 mmol) and DMF (150 mL). The crude was purified by column chromatography using ciclohexane/AcOEt (10:1) as eluent. 5.0 g of 1-azido-3-bromopropane was obtained as a colourless oil (29% yield).

\textsuperscript{1}H-NMR (300 MHz, CDCl\textsubscript{3}) δ (ppm) = 3.49 (t, $J = 6.4$ Hz, 2H, BrCH\textsubscript{2}CH\textsubscript{2}CH\textsubscript{2}N\textsubscript{3}), 3.48 (t, $J = 6.3$ Hz, 2H, BrCH\textsubscript{2}CH\textsubscript{2}CH\textsubscript{2}N\textsubscript{3}), 2.08 (p, 6.4 Hz, 2H, N\textsubscript{1}CH\textsubscript{2}CH\textsubscript{2}CH\textsubscript{2}N\textsubscript{3}).

1-(3-azidoprop-1-yl)-Uracil. Cs\textsubscript{2}CO\textsubscript{3} (9.67 g, 70.0 mmol) was added over a suspension of Uracil (10 g, 89.2 mmol) in dry DMF (225 mL). The mixture was heated to 40°C. After 30 min, 1-azido-3-bromopropane (4.2 g, 25.6 mmol) was added and the mixture was heated to 40°C. After 24 h, the solvent was removed over low pressure and H\textsubscript{2}O (200 mL) was added. After sonication, the mixture was extracted with a CHCl\textsubscript{3}/MeOH mixture (10:1, 3x200 mL). The combined organic phases were dried with MgSO\textsubscript{4} and filtered, and the solvent was eliminated under low pressure. The crude was purified by column chromatography using CHCl\textsubscript{3}/THF (3:1) as eluent. 1.45 g of UR3N3 was obtained as a white solid (29% yield).
**1H-NMR** (300 MHz, CDCl₃) δ (ppm) = 9.12 (s, 1H, N³H), 7.17 (d, J = 7.9 Hz, 1H, H⁶), 5.72 (d, J = 7.9 Hz, 1H, H²), 3.83 (t, J = 6.8 Hz, 2H, N¹CH₂CH₂CH₂N₃), 3.41 (t, J = 6.3 Hz, 2H, N¹CH₂CH₂CH₂N₃), 1.97 (p, 6.7 Hz, 2H, N¹CH₂CH₂CH₂N₃).

**13C-NMR** (75 MHz, CDCl₃) δ (ppm) = 163.5, 150.8, 144.5, 102.4, 48.2, 46.5, 28.0.


**Synthesis of COFs and characterization**

- **Synthesis of [HC≡C]₀.₅-TPB-DMTP-COF**:

![Scheme S1. Synthesis of [HC≡C]₀.₅-TPB-DMTP-COF.](image)

Following the procedure previously described, from **DMTA** (215.3 mg, 1.109 mmol), **BPTA** (268.8 mg, 1.110 mmol), **TAPB** (520.4 mg, 1.481 mmol) and **o-DCB/n-Butanol** (10 mL/10 mL) and acetic acid (6 M, 2.1 mL) in a Pyrex vessel (φ = 29 mm, h = 10 cm) were obtained, after Soxhlet extraction in THF, 866.0 mg (94 %) of a yellow solid. **FTIR (ATR) (cm⁻¹):** 3288, 2957, 2127, 1689, 1592, 1504, 1415, 1291, 1208, 1146, 1036, 878, 829, 694.
Figure S1. FTIR (ATR) spectrum of $[\text{HC≡C}]_{0.5}$-TPB-DMTP-COF.

Figure S2. PXRD pattern of $[\text{HC≡C}]_{0.5}$-TPB-DMTP-COF.
Table S1. PXRD of [HC≡C]_{0.5}-TPB-DMTP-COF.

<table>
<thead>
<tr>
<th>Pos. (°2θ)</th>
<th>d-spacing (Å)</th>
<th>Rel. Int. (%)</th>
<th>FWHM (°2θ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9750</td>
<td>29.698</td>
<td>100</td>
<td>0.3149</td>
</tr>
<tr>
<td>4.9836</td>
<td>17.732</td>
<td>7.81</td>
<td>0.3149</td>
</tr>
<tr>
<td>5.7930</td>
<td>15.256</td>
<td>15.63</td>
<td>0.3542</td>
</tr>
<tr>
<td>7.5515</td>
<td>11.707</td>
<td>7.27</td>
<td>0.3542</td>
</tr>
<tr>
<td>9.8914</td>
<td>8.942</td>
<td>1.64</td>
<td>0.1968</td>
</tr>
<tr>
<td>25.457</td>
<td>3.499</td>
<td>1.21</td>
<td>0.1447</td>
</tr>
</tbody>
</table>

- Synthesis of [Uracil]_{0.5}-TPB-DMTP-COF:

To 100.9 mg of [HC≡C]_{0.5}-TPB-DMTP-COF in 2 mL of anhydrous DMF were added 24.3 mg (0.128 mmol) of CuI and 75 µL of N,N-diisopropylethylamine (DIPEA). The suspension was purged with argon for 5 min and then 51 mg (0.261 mmol) of 1-(3-azidopropyl)uracil were added. The mixture was stirred overnight at room temperature under argon and centrifuged at 6000 rpm for 5 min. After washing with DMF, H₂O and THF, the solid was dried under vacuum at 120 °C yielding an orange powder (151.8 mg, quantitative yield). FTIR (ATR) (cm⁻¹): 3026, 2946, 1682, 1618, 1592, 1507, 1455, 1416, 1373, 1289, 1209, 1145, 1040, 829, 697.

Scheme S2. Synthesis of [Uracil]_{0.5}-TPB-DMTP-COF.
Figure S3. FTIR (ATR) spectrum of [Uracil]$_{0.5}$-TPB-DMTP-COF.

Figure S4. PXRD pattern of [Uracil]$_{0.5}$-TPB-DMTP-COF.
Table S2. PXRD of \([\text{Uracil}]_{0.5}\text{-TPB-DMTP-COF}\).

<table>
<thead>
<tr>
<th>Pos. (°2θ)</th>
<th>d-spacing (Å)</th>
<th>Rel. Int. (%)</th>
<th>FWHM (°2θ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9724</td>
<td>29.724</td>
<td>100</td>
<td>0.2755</td>
</tr>
<tr>
<td>4.9368</td>
<td>17.900</td>
<td>7.85</td>
<td>0.1968</td>
</tr>
<tr>
<td>5.7669</td>
<td>15.325</td>
<td>13.24</td>
<td>0.2755</td>
</tr>
<tr>
<td>7.6366</td>
<td>11.577</td>
<td>3.84</td>
<td>0.3149</td>
</tr>
<tr>
<td>9.8292</td>
<td>8.999</td>
<td>3.37</td>
<td>0.1574</td>
</tr>
<tr>
<td>25.5176</td>
<td>3.491</td>
<td>3.49</td>
<td>0.1574</td>
</tr>
</tbody>
</table>

Figure S5. Comparative FTIR (ATR) spectra of \([\text{HC}≡\text{C}]_{0.5}\text{-TPB-DMTP-COF}\) (black), \([\text{Uracil}]_{0.5}\text{-TPB-DMTP-COF}\) (red), and 1-(3-azidopropyl)uracil (blue).
• Synthesis of TPB-DMTP-COF:\textsuperscript{1}

\[
\begin{align*}
\text{DMTA} & \quad (84.4 \text{ mg, 0.435 mmol}) ,
\text{TAPB} & \quad (102.5 \text{ mg, 0.292 mmol}) \text{ and } \text{o-DCB/n-Butanol (2 mL/2 mL) and acetic acid (6 M, 0.4 mL) in a Pyrex vessel (\( \phi = 18 \text{ mm}, h = 10 \text{ cm} \)) were obtained, after Soxhlet extraction in THF, 162.1 mg (95 \%) of a yellow solid. FTIR (ATR) (cm\textsuperscript{-1}): 2957, 1592, 1504, 1464, 1410, 1290, 1211, 1144, 1042, 879, 823, 639.}
\end{align*}
\]

\textbf{Scheme S3. Synthesis of TPB-DMTP-COF.}

\textbf{Figure S6. FTIR (ATR) spectrum of TPB-DMTP-COF.}
Figure S7. PXRD pattern of TPB-DMTP-COF.

Table S3. PXRD of TPB-DMTP-COF.

<table>
<thead>
<tr>
<th>Pos. (°2θ)</th>
<th>d-spacing (Å)</th>
<th>Rel. Int. (%)</th>
<th>FWHM (°2θ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9531</td>
<td>29.919</td>
<td>100</td>
<td>0.2362</td>
</tr>
<tr>
<td>4.9972</td>
<td>17.684</td>
<td>11.25</td>
<td>0.2755</td>
</tr>
<tr>
<td>5.7309</td>
<td>15.422</td>
<td>15.95</td>
<td>0.3149</td>
</tr>
<tr>
<td>7.5433</td>
<td>11.720</td>
<td>8.92</td>
<td>0.2755</td>
</tr>
<tr>
<td>9.8263</td>
<td>9.001</td>
<td>2.51</td>
<td>0.1968</td>
</tr>
<tr>
<td>25.5271</td>
<td>3.499</td>
<td>1.03</td>
<td>0.1378</td>
</tr>
</tbody>
</table>
• Synthesis of TPB-DMTP-COF-TAZ:\textsuperscript{4}

Scheme S4. Synthesis of TPB-DMTP-COF-TAZ.

34.4 mg (0.18 mmol) of CuI and 129.2 mg of [HC≡C]_{0.5}-TPB-DMTP-COF were suspended in a mixture of THF/H\textsubscript{2}O (3.9/1.7 mL). The suspension was purged with Argon for 5 min and then N,N-diisopropylethylamine (DIPEA) was added (92.7 \textmu L). The mixture was purged with Argon for 5 min and toluene (0.2 mL) and 60 mg of 1-azidopropane\textsuperscript{3} were added. The suspension was stirred overnight at room temperature under argon. The solid was centrifuged with 5 mL of THF. Then, it was washed thoroughly with water, THF and dried, yielding a yellow solid (166 mg). FTIR (ATR) (cm\textsuperscript{-1}): 2965, 2971, 1769, 1591, 1503, 1463, 1414, 1380, 1290, 1146, 1042, 877, 829, 733, 696, 607.
Figure S8. FTIR (ATR) spectrum of TPB-DMTP-COF-TAZ.

Figure S9. PXRD patterns of TPB-DMTP-COF-TAZ.

Table S4. PXRD of TPB-DMTP-COF-TAZ.

<table>
<thead>
<tr>
<th>Small-angle range</th>
<th>Wide-angle range</th>
</tr>
</thead>
<tbody>
<tr>
<td>(°20)</td>
<td>(Å)</td>
</tr>
<tr>
<td>2.7299</td>
<td>32.338</td>
</tr>
<tr>
<td>5.6243</td>
<td>15.714</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S5. Lattice parameters of the synthesized COFs.

<table>
<thead>
<tr>
<th></th>
<th>a=b / Å</th>
<th>c / Å</th>
<th>α=β / º</th>
<th>γ / º</th>
</tr>
</thead>
<tbody>
<tr>
<td>[HC≡C]₀.₅-TPB-DMTP-COF</td>
<td>35.3</td>
<td>3.50</td>
<td>90</td>
<td>120</td>
</tr>
<tr>
<td>[Uracil]₀.₅-TPB-DMTP-COF</td>
<td>35.3</td>
<td>3.49</td>
<td>90</td>
<td>120</td>
</tr>
<tr>
<td>TPB-DMTP-COF</td>
<td>35.4</td>
<td>3.49</td>
<td>90</td>
<td>120</td>
</tr>
<tr>
<td>TPB-DMTP-COF-TAZ</td>
<td>36.6</td>
<td>3.50</td>
<td>90</td>
<td>120</td>
</tr>
</tbody>
</table>

- Nitrogen adsorption isotherms data

Table S6. Surface area, pore volume and pore size of COFs.

<table>
<thead>
<tr>
<th></th>
<th>BET surface area (m² g⁻¹)</th>
<th>Pore volume (cm³ g⁻¹)</th>
<th>Pore size (nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[HC≡C]₀.₅-TPB-DMTP-COF (ref 1)</td>
<td>1642</td>
<td>1.02</td>
<td>3.03</td>
</tr>
<tr>
<td>[HC≡C]₀.₅-TPB-DMTP-COF (this work)</td>
<td>1510</td>
<td>0.94</td>
<td>2.53</td>
</tr>
<tr>
<td>[Uracil]₀.₅-TPB-DMTP-COF</td>
<td>105</td>
<td>0.088</td>
<td>1.30</td>
</tr>
</tbody>
</table>
TGA of COFs

Figure S10. TGA profile of [HC≡C]_{0.5}-TPB-DMTP-COF.

Figure S11. TGA profile of [Uracil]_{0.5}-TPB-DMTP-COF.
Figure S12. TGA profile of TPB-DMTP-COF.

Figure S13. TGA profile of TPB-DMTP-COF-TAZ.
- $^1$H NMR, $^{13}$C NMR and FTIR spectra of starting materials and COFs

$^1$H NMR 1-(3-azidopropyl)uracil

$^{13}$C NMR 1-(3-azidopropyl)uracil
Figure S14. CP/MAS-$^{13}$C NMR of [HC≡C]$_{0.5}$-TPB-DMTP-COF.
Figure S15. CP/MAS-$^{13}$C NMR of [Uracil]$_{0.5}$-TPB-DMTP-COF.

Figure S16. CP/MAS-$^{13}$C NMR of TPB-DMTP-COF-TAZ.
- Elemental Analysis

- **[HC≡C]0.5-TPB-DMTP-COF**
  - Calculated - C: 80.75 %, H: 4.84 %, N: 6.73 %
  - Experimental - C: 78.73 %, H: 5.06 %, N: 6.46 %
  - Experimental - C: 79.20 %, H: 4.99 %, N: 6.48 %
  - Experimental - C: 79.04 %, H: 5.05 %, N: 6.47 %

- **[Uracil]0.5-TPB-DMTP-COF**
  - Calculated – C: 68.73 %, H: 4.78 %, N: 16.03 %
  - Experimental – C: 60.91 %, H: 4.72 %, N: 13.71 %
  - Experimental – C: 61.50 %, H: 4.80 %, N: 14.00 %
  - Experimental – C: 61.39 %, H: 4.76 %, N: 13.78 %

- **TPB-DMTP-COF**
  - Calculated - C: 79.57 %, H: 5.14 %, N: 7.14 %
  - Experimental - C: 78.38 %, H: 5.67 %, N: 6.06 %
  - Experimental - C: 75.56 %, H: 5.43 %, N: 5.83 %
  - Experimental - C: 78.36 %, H: 5.69 %, N: 6.12 %

- **TPB-DMTP-COF-TAZ**
  - Calculated - C: 73.60 %, H: 5.56 %, N: 14.31 %
  - Experimental - C: 64.14 %, H: 4.99 %, N: 10.24 %
  - Experimental - C: 64.58 %, H: 5.00 %, N: 10.27 %
  - Experimental - C: 64.10 %, H: 4.91 %, N: 10.13 %
Figure S17. Concentration of nucleobases in the media after incubation at 150 μM using TPB-DMTP-COF-TAZ (COF-P) and [Uracil]₀.₅-TPB-DMTP-COF (COF-U) for 22 hours. (a) Adenine, (b) Cytosine. The interaction of adenine with [Uracil]₀.₅-TPB-DMTP-COF is superior compared with any other combination. All the experiments were done in triplicates. Statistical analysis was performed using one-way ANOVA Tukey’s test (each group vs Control). *P<0.01, **P<0.001, and ***P<0.0001.

- References